GHRS Key Statistics, Chart & Performance
The current stock price of GHRS is 15.37 USD. In the past month the price increased by 2.4%. In the past year, price increased by 7.41%.
GHRS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GHRS. When comparing the yearly performance of all stocks, GHRS turns out to be only a medium performer in the overall market: it outperformed 62.33% of all stocks.
GHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GHRS. While GHRS seems to be doing ok healthwise, there are quite some concerns on its profitability.
GHRS Financial Highlights
Over the last trailing twelve months GHRS reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 6.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.21% | ||
| ROE | -14.73% | ||
| Debt/Equity | 0 |
GHRS Forecast & Estimates
15 analysts have analysed GHRS and the average price target is 34.42 USD. This implies a price increase of 123.98% is expected in the next year compared to the current price of 15.37.
GHRS Ownership
GHRS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.12 | 1T | ||
| JNJ | JOHNSON & JOHNSON | 20.48 | 578.208B | ||
| MRK | MERCK & CO. INC. | 21.74 | 302.633B | ||
| PFE | PFIZER INC | 9.01 | 154.765B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.99 | 126.196B | ||
| ZTS | ZOETIS INC | 18.54 | 56.153B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.49 | 25.774B | ||
| VTRS | VIATRIS INC | 6.15 | 16.793B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.75 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.72 | 9.202B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GHRS
Company Profile
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Company Info
GH RESEARCH PLC
Joshua Dawson House, Dawson Street
DUBLIN LEINSTER IE
CEO: Theis Terwey
Employees: 50
Phone: 35314378334
GH RESEARCH PLC / GHRS FAQ
What does GH RESEARCH PLC do?
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 50 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Can you provide the latest stock price for GH RESEARCH PLC?
The current stock price of GHRS is 15.37 USD. The price increased by 1.35% in the last trading session.
Does GH RESEARCH PLC pay dividends?
GHRS does not pay a dividend.
What is the ChartMill rating of GH RESEARCH PLC stock?
GHRS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for GHRS stock?
15 analysts have analysed GHRS and the average price target is 34.42 USD. This implies a price increase of 123.98% is expected in the next year compared to the current price of 15.37.
Should I buy GHRS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GHRS.